FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322012331> ?p ?o ?g. }

• W4322012331 endingPage "21" @default.
• W4322012331 startingPage "12" @default.
• W4322012331 abstract "Beyond improving hemoglobin A1c (HbA1c) in adults with type 2 diabetes, glucagon-like peptide 1 receptor agonists (GLP-1RA) have been approved for reducing risk of major adverse cardiovascular events (MACE) with established cardiovascular disease (CVD) or multiple CV risk factors. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) also reduced the risk for the primary composite CV outcome in patients with type 2 diabetes at high risk for CV events. In the American Diabetes Association (ADA) and European Association of Study in Diabetes (EASD) consensus report 2022, there is the description “In people with established atherosclerotic CVD (ASCVD) or with a high risk for ASCVD, GLP-1RA were prioritized over SGLT2i”; however, the evidence supporting such statement is limited. Therefore, we studied the superiority of GLP-1RA over SGLT2i for prevention of ASCVD from various viewpoints. We could not find a meaningful difference in the risk reduction in three-point MACE (3P-MACE), mortality due to any cause, mortality due to CV cause and nonfatal myocardial infarction between GLP-1RA and SGLT2i trials. The risk of nonfatal stroke decreased in all five GLP-1RA trials; however, two of three SGLT2i trials showed an increase in risk of nonfatal stroke. The risk of hospitalization for heart failure (HHF) decreased in all three SGLT2i trials, and one GLP-1RA trial showed an increase in risk of HHF. The risk reduction of HHF in SGLT2i trials was greater than that in GLP-1RA trials. These findings were consistent with current systematic reviews and meta-analyses. The risk reduction of 3P-MACE was significantly and negatively correlated with changes in HbA1c (R = -0.861, P = 0.006) and body weight (R = -0.895, P = 0.003) in GLP-1RA and SGLT2i trials. The studies using SGLT2i failed to reduce carotid intima media thickness (cIMT), the surrogate marker for atherosclerosis; however, several studies using GLP-1RA successfully reduced cIMT in patients with type 2 diabetes. Compared with SGLT2i, GLP-1RA had a higher probability of decreasing serum triglyceride. GLP-1RA have multiple vascular biological anti-atherogenic properties. Cardiol Res. 2023;14(1):12-21 doi: https://doi.org/10.14740/cr1459" @default.
• W4322012331 created "2023-02-26" @default.
• W4322012331 creator A5003691461 @default.
• W4322012331 creator A5041096052 @default.
• W4322012331 creator A5046654268 @default.
• W4322012331 creator A5051258968 @default.
• W4322012331 date "2023-02-01" @default.
• W4322012331 modified "2023-10-01" @default.
• W4322012331 title "Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes" @default.
• W4322012331 cites W1496311362 @default.
• W4322012331 cites W1700218887 @default.
• W4322012331 cites W1966379378 @default.
• W4322012331 cites W1973442218 @default.
• W4322012331 cites W2013730613 @default.
• W4322012331 cites W2015506365 @default.
• W4322012331 cites W2022716066 @default.
• W4322012331 cites W2024031438 @default.
• W4322012331 cites W2026885016 @default.
• W4322012331 cites W2030809658 @default.
• W4322012331 cites W2046214798 @default.
• W4322012331 cites W2054506478 @default.
• W4322012331 cites W2062265409 @default.
• W4322012331 cites W2075024723 @default.
• W4322012331 cites W2109677274 @default.
• W4322012331 cites W2112912403 @default.
• W4322012331 cites W2128077095 @default.
• W4322012331 cites W2133617810 @default.
• W4322012331 cites W2134077483 @default.
• W4322012331 cites W2146264128 @default.
• W4322012331 cites W2154828885 @default.
• W4322012331 cites W2161739223 @default.
• W4322012331 cites W2321992706 @default.
• W4322012331 cites W2329234205 @default.
• W4322012331 cites W2338967005 @default.
• W4322012331 cites W2425644022 @default.
• W4322012331 cites W2519510391 @default.
• W4322012331 cites W2528366375 @default.
• W4322012331 cites W2558288750 @default.
• W4322012331 cites W2618856448 @default.
• W4322012331 cites W2626446274 @default.
• W4322012331 cites W2735594337 @default.
• W4322012331 cites W2754041380 @default.
• W4322012331 cites W2804862484 @default.
• W4322012331 cites W2890285768 @default.
• W4322012331 cites W2891070912 @default.
• W4322012331 cites W2895533920 @default.
• W4322012331 cites W2900413769 @default.
• W4322012331 cites W2901634147 @default.
• W4322012331 cites W2948612418 @default.
• W4322012331 cites W2963090082 @default.
• W4322012331 cites W3010363078 @default.
• W4322012331 cites W3020130780 @default.
• W4322012331 cites W3033040359 @default.
• W4322012331 cites W3037508799 @default.
• W4322012331 cites W3038341420 @default.
• W4322012331 cites W3041394830 @default.
• W4322012331 cites W3093042356 @default.
• W4322012331 cites W3120821309 @default.
• W4322012331 cites W3126209743 @default.
• W4322012331 cites W3199651111 @default.
• W4322012331 cites W3201795055 @default.
• W4322012331 cites W4206445899 @default.
• W4322012331 cites W4283735616 @default.
• W4322012331 cites W4285083553 @default.
• W4322012331 cites W4296802076 @default.
• W4322012331 cites W4301595733 @default.
• W4322012331 cites W4307585181 @default.
• W4322012331 doi "https://doi.org/10.14740/cr1459" @default.
• W4322012331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36896226" @default.
• W4322012331 hasPublicationYear "2023" @default.
• W4322012331 type Work @default.
• W4322012331 citedByCount "3" @default.
• W4322012331 countsByYear W43220123312023 @default.
• W4322012331 crossrefType "journal-article" @default.
• W4322012331 hasAuthorship W4322012331A5003691461 @default.
• W4322012331 hasAuthorship W4322012331A5041096052 @default.
• W4322012331 hasAuthorship W4322012331A5046654268 @default.
• W4322012331 hasAuthorship W4322012331A5051258968 @default.
• W4322012331 hasBestOaLocation W43220123311 @default.
• W4322012331 hasConcept C126322002 @default.
• W4322012331 hasConcept C127413603 @default.
• W4322012331 hasConcept C134018914 @default.
• W4322012331 hasConcept C164705383 @default.
• W4322012331 hasConcept C2777180221 @default.
• W4322012331 hasConcept C2780400711 @default.
• W4322012331 hasConcept C2780645631 @default.
• W4322012331 hasConcept C2780739214 @default.
• W4322012331 hasConcept C2910068830 @default.
• W4322012331 hasConcept C500558357 @default.
• W4322012331 hasConcept C555293320 @default.
• W4322012331 hasConcept C71924100 @default.
• W4322012331 hasConcept C78519656 @default.
• W4322012331 hasConceptScore W4322012331C126322002 @default.
• W4322012331 hasConceptScore W4322012331C127413603 @default.
• W4322012331 hasConceptScore W4322012331C134018914 @default.
• W4322012331 hasConceptScore W4322012331C164705383 @default.
• W4322012331 hasConceptScore W4322012331C2777180221 @default.
• W4322012331 hasConceptScore W4322012331C2780400711 @default.

• next